WO2021127769A1

WO2021127769A1 - Composition for treating conjunctivitis

Info

Publication number: WO2021127769A1
Application number: PCT/BR2020/050580
Authority: WO
Inventors: Antonio Roberto NARDINI
Original assignee: Nardini Antonio Roberto
Priority date: 2019-12-24
Filing date: 2020-12-23
Publication date: 2021-07-01
Also published as: BR102019027801A2

Abstract

The present invention pertains to the pharmaceutical sector, and more specifically proposes a composition for treating conjunctivitis. The compound is made of common ingredients popularly known as healthy ingredients with properties rich in vitamins, oils and proteins. The novel compound contains natural components with quantities of milk or milk component and the plant Ruta graveolens, better known as common rue. These are components known to contain vitamins and to have different anti-inflammatory and antibiotic properties. Finally, another objective of the invention is to provide a complete treatment for conjunctivitis in 12 hours, applying a droplet of natural eye drops every 4 hours. In general, the composition proposed in the present patent application comprises 10-15% milk or milk component by volume, 0.05-5% Ruta graveolens by volume, and 80-89% saline by volume.

Description

COMPOSITION FOR TREATMENT OF CONJUNCTIVITIS Technological sector of the invention

[001] The present invention refers to the pharmaceutical area, more specifically, it proposes a composition for the treatment of conjunctivitis. The compound is made up of common ingredients and popularly known as healthy ingredients with properties rich in vitamins, oils and proteins.

Known prior art

[002] Conjunctivitis is the name given when inflammation occurs in the conjunctiva of the eye and the inner surface of the eyelid. The conjunctiva is the outer layer of the white part of the eye. Conjunctivitis causes discharge in the eyes, in addition to making them red, which may be followed by pain, burning and itching.

[003] In Brazil, outbreaks of conjunctivitis occur annually, mainly during the spring and summer season, as the heat and humidity favor the spread of infectious agents. According to the BBC website, to date, the biggest outbreak of conjunctivitis in Brazil occurred in 2018, starting in December 2017. According to the Ministry of Health, in early summer it is normal to have outbreaks of conjunctivitis, however, in 2018, in addition to having infected more people, the outbreak lasted longer and may be related to the length of the carnival, according to some doctors interviewed by the BBC.

[004] There are three types of conjunctivitis, infectious, allergic and toxic conjunctivitis. The most common and most common is infectious, especially in adults, mainly because of the ease of contamination. Infectious conjunctivitis can occur via the adenovirus, enterovirus 70, and coxackie A4 viruses, causing it mainly in closed places, such as schools, workplaces and doctors' offices. The common treatment for viral infectious conjunctivitis is with cold compresses and artificial tears. [005] Infectious conjunctivitis can also occur via the bacteria Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae. This conjunctivitis is characterized by having a large volume of ocular secretion. The recommended treatment for bacterial infectious conjunctivitis is the use of antibiotics in the form of eye drops.

[006] There is still bacterial infectious conjunctivitis caused by the bacterium Neisseria gonorrhoeae, called as gonococcal conjunctivitis, which is sexually transmitted or at the time of delivery, which is rarer. The treatment for this conjunctivitis in question is based on the application of systemic and ocular antibiotics, once untreated, the causing bacteria can penetrate the intact eye and consume it, causing the person to lose the infected eye. [007] There is still bacterial infectious conjunctivitis caused by the bacterium Chlamydia trachomatis, known as inclusion conjunctivitis, or trachoma. It has a longer duration and usually affects sexually active young people. Treatment is with the application of azithromycin or doxycycline.

[008] And yet there is fungal conjunctivitis is rarer to occur. It usually happens when a person is injured with wood in their eyes or wears a contact lens.

[009] The transmission of infectious conjunctivitis occurs through direct contact with the patient or indirectly through contact with objects contaminated by the infectious agent. The secretion resulting from the inflammatory process in the eyes serves as a vehicle for the transmission of the microbe. The person with conjunctivitis rubs their eyes and then shakes hands with someone, or touches the door handles, elevator buttons, remote control, computer keyboard, stair rail, bus or bus supports. subway, and leaves the micro-organism there that, depending on the type, can survive for hours outside the body. So, just someone touch these surfaces and put the hand over the eyes for the disease to spread. With that, it is possible to notice that the infection happens simply and quickly.

[010] Although infectious conjunctivitis is the most common to occur, conjunctivitis can occur via allergies, which occurs in people predisposed to allergies. It occurs periodically and may occur due to the presence of common allergens, such as pollen and mold, in regions with a colder climate. This conjunctivitis is treated with antihistamines, but it can go away over time if the cause is treated.

[011] Finally, there is toxic conjunctivitis, caused by direct contact with some toxic agent, which can be some medicated eye drops or some cleaning products, cigarette smoke and industrial pollutants. Some other irritants that can cause toxic conjunctivitis are air pollution, soap, soap, spray, makeup, chlorine, and hair dyes. A person with toxic conjunctivitis should move away from the causative agent and wash their eyes with plenty of water. If the cause is drug use, it is necessary to discontinue use, always following medical advice.

[012] As we can see, infectious conjunctivitis is the most common, being the focus of conjunctivitis epidemics in the world. Because of this, the pharmaceutical industry has different eye drops to fight infectious conjunctivitis. However, these conventional eye drops comprise a large number of chemical compositions, which take around 5 to 7 days to carry out the conjunctivitis cure process.

[013] Furthermore, as we can note in the above, each conjunctivitis has its own treatment, differentiating the composition of each eyedrop. This allows for a medical error when treating conjunctivitis, which may, in some cases, worsen the situation of the infected person.

[014] With this in mind, eye drops comprising natural compounds for the treatment of conjunctivitis appeared on the market, and some with a record of patent, such as patent document JP2018083788, entitled "COMPOSITION FOR PREVENTION AND/OR IMPROVEMENT OF ALLERGIC DISEASE WHICH CONTAINS HYDROGEN ABSORBED SILICA AS ACTIVE INGREDIENT which describes the use, among other components, of quercetin for the treatment of conjunctivitis. which has anti-inflammatory properties, making it effective in the treatment of allergic conjunctivitis. However, the document in question does not present the necessary vitamins and substances for the treatment of infectious conjunctivitis, only allergic conjunctivitis.

[015] Patent document JPH11189533, entitled as 'UE DROP' describes the use of vitamins A, B, E and B12, which are recognized as important in an eye treatment. However, the document in question does not have anti-inflammatory features, an essential feature in the treatment of allergic conjunctivitis.

[016] Patent document MX2014015124, entitled "PH THE RMA CEUTICAL COMPOSITION FOR OPTHALMIC USE, WHICH INCLUDES ZINC, NIACIN, COCARBOXYLASE, VITAMIN C, HYALURONIC ACID, GLUTATHIONE, MAGNESIUM, CHROMIUM AND SELENIUM describes the use of vitamin" other components for treating diseases related to the human eye. As is technically known, vitamin C is recommended for the treatment of diseases caused by viruses, such as, for example, Viral Conjunctivitis. However, the document in question does not have anti-inflammatory features, an essential feature in the treatment of allergic conjunctivitis.

[017] The document CN102805865, entitled as "Eye drop administration device system and preparation" describes an eye drop mainly composed of antibodies. As is technically known, antibodies are used to treat contagious or bacterial diseases. Thereby, the document provides for the use of antibodies to treat conjunctivitis. However, the document in question does not have anti-inflammatory features, an essential feature in the treatment of allergic conjunctivitis.

[018] The document CN103704412, entitled as "Milk tea electuary for curing pleural effusion conjunctivitis" describes the use of milk in a compound created for the treatment of conjunctivitis by pleural emulsion. However, the document in question does not have anti-inflammatory features, an essential feature in the treatment of allergic conjunctivitis.

[019] As we can note, the state of the art is failing to present a natural eye drops, which can perform the treatment of more than one type of conjunctivitis. Furthermore, few documents showed the use of natural substances, using chemical compounds, using vitamins present in different natural products that could perform a complete treatment of conjunctivitis, without the use of chemical compounds. News and objectives of the invention

[020] The present application for a patent of invention proposes an innovative compound that comprises natural components with amounts of milk or dairy compound and Ruta graveolens plant, better known as rue. Components known to comprise vitamins and different anti-inflammatory and antibiotic properties.

[021] This compound, being used in the form of eye drops can perform a complete treatment, avoiding pain and other inconvenience or discomfort for the patient. Furthermore, the compound differs from drugs known on the market for having a natural composition, making the treatment safer and avoiding side effects, since the patient will not ingest chemical compounds that can cause other health problems, being effective in the treatment of viral conjunctivitis, bacterial and allergic. In addition, eye drops are able to cure the infection, while eye drops perform a symptomatic treatment of allergic conjunctivitis [022] Finally, another objective of the invention is to perform the complete treatment of conjunctivitis in 12 hours, applying a drop of natural eye drops , every 4 hours. Detailed description of the invention

[023] The compound proposed by the present invention provides sufficient amounts of milk or dairy compound and Ruta graveolens leaves. Preferably this composition should be administered to patients through eye drops. [024] In general, the composition proposed in this patent application comprises milk or milk compound in the amount of 10 - 15% by volume, Ruta graveolens in the amount of 0.05 - 5% by volume and saline in the amount of 80 - 89% by volume.

[025] More specifically, the present invention proposes a composition comprising 13% milk or dairy compound, 3% Ruta graveolens and 84% saline.

[026] The milk or dairy compound used in the present invention should comprise high protein content, in which said whey proteins constitute about 60 to 90% of its total protein content. The milk or milk compound in question comprises amounts of alpha-lactalbumin, lactoferrin, lysozyme, serum albumin, immunoglobulins and beta-lactoglobulin. Alpha-lactalbumin, which makes up about 40% of proteins. It also comprises peptides with beta-casein (50%) and kappa-casein (20 to 27%) fractions; it may further comprise amounts of bombesin, colocystokinin and neurotensin.

[027] Amounts of micronutrients are also desirable in this milk or dairy compound, being mineral components, the macrominerals of the group that include: sodium, potassium, chloride, calcium, magnesium, phosphorus and sulfate. [028] Finally, the compound also comprises vitamins such as: vitamin B6 (pyridoxine), B2 (riboflavin), vitamin A, vitamin E, vitamins D2 (ergocalciferol) and D3 (cholecalciferol), vitamin D, vitamin K1 (phyloquinone ) and vitamin K2 (menaquinone). [029] The compound should be presented to the patient in the form of eye drops, to be properly applied as a drop in the patient's eye. Preferably, patients should enjoy this compound for 12 hours, applying a drop of natural eye drops every 4 hours. With this, the natural remedy can treat and prevent the disease known as infectious and allergic conjunctivitis.

[030] A preferred alternative specifically provides for the use of milk or compost in the composition. Considering then that this milk is breast milk. Therefore, the present invention proposes a composition comprising breast milk in the amount of 10 - 15% in volume, Ruta graveolens in the amount of 0.05 - 5% in volume and saline in the amount of 80 - 89% in volume. More specifically, the present proposed composition foresees 13% of Breast Milk, 3% of Ruta graveolens and 84% of Saline.

[031] The milk or dairy compound should be rich in proteins, vitamins, enzymes and minerals. More specifically, breast milk is still rich in white blood cells and antibodies and comprises vitamins A, C, D, E and B12, which help the patient's eye health. Vitamin C, in addition to containing oxidants that help fight viruses and bacteria, helps retain other vitamins. Vitamin E, which is also rich in oxidants, helps protect the eye's membranes, which can be damaged during conjunctivitis. Vitamin B12, on the other hand, prevents the patient from having spasms in the lower area of the eyes and eyelids. Furthermore, breast milk still comprises proteins, white blood cells and antibodies, which act on the immune system, fighting and protecting from various infections, such as viruses and bacteria, the main causes of infectious conjunctivitis, and protecting the nervous system of the eye. [032] In addition, the compound of the invention now detailed comprises leaves of Ruta graveolens, inserted in powder or oil format, known as stink rue, house rue, garden ruta and strong-smelling ruta, is a plant of the Rutaceous family, and is scientifically called Ruta graveolens. A plant rich in antioxidants and popularly known for promoting anti-inflammatory effects, due to its active component quercetin. Furthermore, the leaf of Ruta graveolens comprises rutin, which is known to be an antibacterial substance. Because of these characteristics, the Ruta graveolens leaf fights inflammation caused by allergic and toxic conjunctivitis, in addition to fighting bacteria from bacterial infectious conjunctivitis.

[033] To complete the composition, both natural components mentioned above are mixed with saline, known to promote lubrication and hydration of the eye.

[034] For such treatment, a formulation in eye drops of the previously mentioned components is suggested. The treatment, preferably, would be the application of one drop of this eye drops every 4 hours, for 12 hours. With this, the treatment for allergic, viral and bacterial conjunctivitis would be complete, eliminating the bacteria and viruses from the eye, as well as deinflaming the same. Furthermore, the eye drops in question revitalizes the eye, generating protection against other contaminations during the treatment.

[035] As stated earlier, bacterial and viral conjunctivitis is caused by the action of certain bacteria and viruses on the conjunctiva of the eye, a thin membrane located in the white part of the eye. Because of this, it is understood that an eyedrop with natural components, having characteristics vitamins and substances that can fight the infection, it is expected that this eyedrop can fight the bacterial and viral conjunctivitis, and, since it has proteins and minerals that revitalize and protect the eye, the treatment for bacterial and viral conjunctivitis would be complete, since, in addition to promoting a cure for the infected eye, the same eye drops bring benefits for the same, with protection against other infections and relief from pain and irritation.

[036] Furthermore, it is worth noting that, although allergic conjunctivitis has unknown origins, the anti-inflammatory process, caused by the presence of the properties of Ruta graveolens, and the revitalization process, caused by the vitamins, proteins and minerals present in the milk or dairy compound, promotes relief in pain and irritation of the eye, making the user have a better quality of life, until, naturally, the allergic process improves. [037] This descriptive report deals with a compound for the treatment of viral, bacterial and allergic conjunctivitis, comprising natural components and supplied as eye drops, endowed with novelty, inventive step, descriptive sufficiency, industrial application and, consequently, coated with all the essential requirements for granting the claimed privilege.

Claims

1. COMPOSITION characterized by comprising 10 - 15% by volume of milk or dairy compound, 0.05 - 5% by volume of Ruta graveolens and 80 - 89% by volume of saline.

2. COMPOSITION, according to claim 1, characterized in that said milk or milk compound comprises high protein content in which said whey proteins constitute about 60 to 90% of its total protein content.

3. COMPOSITION according to claim 1, characterized in that said milk or milk compound comprises amounts of alpha-lactalbumin, lactoferrin, lysozyme, serum albumin, immunoglobulins and beta-lactoglobulin.

4. COMPOSITION according to claim 1, characterized in that said milk or milk compound comprises peptides with beta-casein (50%) and kappa-casein (20 to 27%) fractions.

5. COMPOSITION according to claim 1, characterized in that said milk or milk compound comprises macrominerals from the group which includes: sodium, potassium, chloride, calcium, magnesium, phosphorus and sulfate.

6. COMPOSITION according to claim 1, characterized in that said milk or milk compound comprises vitamins from the group which includes: vitamin B6 (pyridoxine), B2 (riboflavin), vitamin B12, vitamin C, vitamin A, vitamin E, vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), vitamin D, vitamin K1 (phyloquinone) and vitamin K2 (menaquinone).

7. COMPOSITION according to claim 1, characterized in that Ruta graveolens is introduced in the powder or oil composition.

8. COMPOSITION, according to claim 1, characterized in that the composition's milk is breast milk.

9. COMPOSITION according to claim 1, characterized in that it comprises 13% breast milk, 3% Ruta graveolens and 84% saline.

10. COMPOSITION according to claim 1, characterized in that it comprises natural ingredients to be administered via drops.

11. USE OF COMPOSITION according to claim 1, characterized in that it is to prepare a drug for the treatment of infectious or allergic conjunctivitis.